Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 3	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 4	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 5	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 6	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 7	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 8	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 9	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 10	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 11	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 12	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 13	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 14	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 15	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 16	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 17	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 18	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 19	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 20	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 21	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 22	JUL 28	CA/CAplus patent coverage enhanced
NEWS 23	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 24	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 25	JUL 28	STN Viewer performance improved
NEWS 26	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 27	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 28	AUG 15	CAOLD to be discontinued on December 31, 2008

```
 NEWS 29  AUG 15  CAplus currency for Korean patents enhanced
 NEWS 30  AUG 25  CA/CAplus, CASREACT, and IFI and USPAT databases
                  enhanced for more flexible patent number searching

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:04:32 ON 27 AUG 2008

=>  file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:04:41 ON 27 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 AUG 2008  HIGHEST RN 1043895-06-2
DICTIONARY FILE UPDATES:  26 AUG 2008  HIGHEST RN 1043895-06-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10522250.str
```





chain nodes :
9 10 11
ring nodes :
1 2 3 4 5 6 7 8
chain bonds :
1-11 3-9 9-10
ring bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-8 6-7 7-8
exact/norm bonds :
1-2 1-5 1-11 2-3 3-4 3-9 4-5 4-6 5-8 6-7 7-8 9-10
isolated ring systems :
containing 1 :

G1:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS 11:CLASS

L1 STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY 0.46 TOTAL SESSION 0.67

FILE 'CAPLUS' ENTERED AT 12:05:00 ON 27 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Aug 2008 VOL 149 ISS 9
FILE LAST UPDATED: 26 Aug 2008 (20080826/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s L1 SSS full
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 12:05:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 534 TO ITERATE

100.0% PROCESSED 534 ITERATIONS 315 ANSWERS
SEARCH TIME: 00.00.01

L2 315 SEA SSS FUL L1

L3 18 L2

=> file marpat
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 0.48 179.99

FILE 'MARPAT' ENTERED AT 12:05:09 ON 27 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 149 ISS 7 (20080822/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 20080167493 10 JUL 2008
DE 102007009957 03 JUL 2008
EP 1939208 02 JUL 2008
JP 2008159496 10 JUL 2008
WO 2008086729 24 JUL 2008
GB 2444641 11 JUN 2008
FR 2910897 04 JUL 2008
RU 2330028 27 JUL 2008
CA 2615024 14 JUN 2008

Expanded G-group definition display now available.

Effective December 15th the iteration and answer limits in MARPAT have increased from 100,000 to 200,000 for both on-line and batch searches. For more information on MARPAT search limits, type HELP SLIMITS at an arrow prompt.

=> s L1 SSS full
FULL SEARCH INITIATED 12:05:13 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 2321 TO ITERATE

100.0% PROCESSED 2321 ITERATIONS 14 ANSWERS
SEARCH TIME: 00.00.02

L4 14 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 125.26 305.25

FILE 'CAPLUS' ENTERED AT 12:05:21 ON 27 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 27 Aug 2008 VOL 149 ISS 9
FILE LAST UPDATED: 26 Aug 2008 (20080826/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s L4
L5   14 L4

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):y

L5   ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:286200 CAPLUS Full-text
DOCUMENT NUMBER: 148:278900
TITLE: Fused heterocyclic inhibitors of D-amino acid oxidase
                         for treatment of neurological disorders, pain, ataxia,
                         and convulsion
INVENTOR(S):   Heffernan, Michele L. R.; Dorsey, James M.; Fang, Qun
                         Kevin; Foglesong, Robert J.; Hopkins, Seth C.; Jones,
                         Michael L.; Jones, Steven W.; Ogbu, Cyprian O.;
                         Perales, Joe B.; Soukri, Mustapha; Spear, Kerry L.;
                         Varney, Mark A.
PATENT ASSIGNEE(S):   Sepracor Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 111pp.
                         CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080058395	A1	20080306	US 2007-825093	20070702
US 20080004327	A1	20080103	US 2007-772798	20070702
WO 2008005456	A2	20080110	WO 2007-US15396	20070702
WO 2008005456	A3	20080731		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20080004328	A1	20080103	US 2007-833903	20070803

PRIORITY APPLN. INFO.:	US 2006-806391P	P	20060630
	US 2006-842465P	P	20060905
	US 2007-914293P	P	20070426
	US 2007-825093	A2	20070702

OTHER SOURCE(S): MARPAT 148:278900
GI



I

AB This invention provides novel inhibitors I (Q = O, S, CR1, N; X, Y = O, S, N, CR2, NR3; R1 = H, F, (substituted)arylakyl, etc.; R2 = H, F, (substituted)-C3-6-alkyl, etc.; R3 = H, (substituted)-C1-6-alkyl, etc.; R4 = H, F, Cl, Br, CN, C1-6-alkyl, etc.; R6 = O-X+, OH; X+ = organic/inorg. pos. ion; when Q = CF and X or Y = S and Y or X = CH then R4 is not H; when Q = CH, then at least one of R2 and R4 is not H) of the enzyme D-amino acid oxidase as well as pharmaceutical compns. including the compds. of the invention. Also provided are methods for the treatment and prevention of neurol. disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion.

L5 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1146039 CAPLUS Full-text
DOCUMENT NUMBER: 147:440293
TITLE: Use of thienopyrazole derivative ABL kinase inhibitors for the treatment of resistant tumors, and screening method
INVENTOR(S): Fancelli, Daniele; Isacchi, Antonella; Modugno, Michele; Moll, Jurgen; Rusconi, Luisa; Soncini, Chiara; Lupi, Rosita
PATENT ASSIGNEE(S): Nerviano Medical Sciences S.r.l., Italy
SOURCE: PCT Int. Appl., 43pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007113198	A2	20071011	WO 2007-EP53013	20070329
WO 2007113198	A3	20080320		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2006-112026 A 20060330
OTHER SOURCE(S): MARPAT 147:440293

AB The invention provides low mol. weight compds., namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compds. are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor- resistant T315I ABL mutants. The compds. of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, e.g. imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compds. capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.

L5 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:85753 CAPLUS Full-text
DOCUMENT NUMBER: 146:184454
TITLE: Preparation of 1H-thieno[2,3-c]pyrazoles as kinase, particularly Aurora kinases and IGF-1R inhibitors for treating cancer
INVENTOR(S): Fancelli, Daniele; Moll, Juergen; Pulici, Maurizio; Quartieri, Francesca; Bandiera, Tiziano
PATENT ASSIGNEE(S): Nerviano Medical Sciences S.r.l., Italy
SOURCE: PCT Int. Appl., 69pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007009898	A1	20070125	WO 2006-EP64055	20060710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1904503	A1	20080402	EP 2006-764123	20060710
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: EP 2005-106602 A 20050719
WO 2006-EP64055 W 20060710
OTHER SOURCE(S): MARPAT 146:184454
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = hetero/aryl on which the substituent -NHZR5 is at the ortho position to the CONH linker; R1, R2 = independently H, alkyl, CONH2, etc.; or R1CR2 = cycloalkyl; R3 = H, halo, OH, CN, alkyl, di/alkylamino, alkoxy; R4 = H, halo, alkoxy, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl,

etc.; Z = a bond, CO, C(:O)NH; R5 = H, (un)substituted cycloalkyl, alk(en)yl, aryl, etc.; and their isomers, tautomers, carriers, metabolites, prodrugs, and pharmaceutically acceptable salts] were prepared as protein kinase, especially Aurora kinases and IGF-1R, inhibitors. I, and their pharmaceutical compns., are useful in the treatment of diseases caused by and/or associated with a dysregulated protein kinase, such as cancer and cell proliferation disorders. E.g., a multi-step synthesis starting from Et 4-cyano-5-(methylthio)thiophene-2-carboxylate was given for thienopyrazole II. II was tested as Aurora-2 kinase inhibitor (IC50 = 6 nM) and for its HCT-116 colon cancer cell antiproliferative effect (IC50 = 7 nM).

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:916512 CAPLUS Full-text

DOCUMENT NUMBER: 145:314984

TITLE: Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, their preparation, compositions containing them and their use as inhibitors of protein kinases

INVENTOR(S): Barberis, Claude; Carry, Jean-Christophe; Doerflinger, Gilles; Barbalat-Damour, Dominique; Clerc, Francois-Frederic; Minoux, Herve

PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.

SOURCE: PCT Int. Appl., 138pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006092510	A1	20060908	WO 2006-FR480	20060303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
FR 2882751	A1	20060908	FR 2005-2199	20050304
FR 2882751	B1	20070914		
AU 2006219805	A1	20060908	AU 2006-219805	20060303
CA 2599270	A1	20060908	CA 2006-2599270	20060303
EP 1858898	A1	20071128	EP 2006-726018	20060303
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008531663	T	20080814	JP 2007-557544	20060303
US 20080146542	A1	20080619	US 2007-846669	20070829
MX 200710753	A	20071107	MX 2007-10753	20070903
KR 2007113214	A	20071128	KR 2007-720106	20070903
IN 2007KN03327	A	20080118	IN 2007-KN3327	20070907
CN 101151268	A	20080326	CN 2006-80010837	20070929
PRIORITY APPLN. INFO.:			FR 2005-2199 A	20050304

WO 2006-FR480 W 20060303

OTHER SOURCE(S): CASREACT 145:314984; MARPAT 145:314984

GI



I



II

AB Title compds. I [R1 = independently NHCOR2, NHCONHR2, NHCOOR2; R2 = H, (un)substituted cyclo/alkyl, hetero/aryl, etc.; R3-R5 = independently H, (un)substituted alkyl, alkyl/aryl, alkyl/heteroaryl; or NR3R4 = (un)substituted heterocyclyl; etc.] were prepared as inhibitors of protein kinases, particularly Aurora 2 kinase (data) for treating cancer (no data). E.g., a 7-step synthesis starting from 3,4,5-tribromopyrazole was given for thienopyrazole II. II inhibited Aurora 1, Aurora 2, CDK2 and Tie2 with IC50 of 8 nM, 8 nM, 177 nM, and 117 nM, resp. I are useful for treating neoplasm, psoriasis, glaucoma, leukemias, inflammations, etc.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:578191 CAPLUS Full-text

DOCUMENT NUMBER: 145:46049

TITLE: Preparation of thienopyridinyl ureas and carbamates as vanilloid receptor subtype 1 (VR1) inhibitors

INVENTOR(S): Turner, Sean C.; Jinkerson, Tammie K.; Gomtsyan, Arthur R.; Lee, Chih-Hung

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006063178	A2	20060615	WO 2005-US44500	20051207
WO 2006063178	A3	20060824		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

US 20060148843	A1	20060706	US 2005-293012		20051202
CA 2590585	A1	20060615	CA 2005-2590585		20051207
EP 1824860	A2	20070829	EP 2005-853428		20051207
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
JP 2008523087	T	20080703	JP 2007-545642		20051207
MX 200706854	A	20070725	MX 2007-6854		20070607
PRIORITY APPLN. INFO.:			US 2004-633957P	P	20041207
			WO 2005-US44500	W	20051207

OTHER SOURCE(S): CASREACT 145:46049; MARPAT 145:46049

GI



I



II

AB Title compds. I [wherein a = absent or bond; X1 = N or CR1; X2 = N or CR2; X3 = N, NR3 or CR3; X4 = absent, N or CR4; X5 = N or CH2; X6, Z1 = O, NH or S; Z2 = NH or O; L = aryl, alkenylene, alkynylene, etc.; R1 - R5 = H, alkenyl, alkoxy, etc.; R6 = H or alkyl; R7 = H or (hetero)aryl, with limitations] and pharmaceutically acceptable salts or prodrugs thereof, such as II, were prepared as antagonists of vanilloid receptor subtype 1 (VR1) receptors. Compds. I were found to be antagonists of human VR1 receptors with IC50 values from 5000 nM to 0.1 nM in a in vitro assay. Two compds. were tested for their in vivo antinociceptive effect using mice and had ED50 values of 30 and 10 μmol/kg, resp. Therefore, I and their pharmaceutical compns. are useful for treating disorders which are ameliorated by inhibiting VR1 receptors, such as pain, urinary incontinence, bladder overactivity and inflammatory thermal hyperalgesia.

L5 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2006:510459 CAPLUS Full-text
DOCUMENT NUMBER:	145:8163
TITLE:	Substituted 1H-thieno[2,3-c]pyrazoles, their preparation, compositions containing them and their use as inhibitors of protein kinases for treating cancer
INVENTOR(S):	Carry, Jean-Christophe; Doerflinger, Gilles; Bigot, Antony; Barbalat-Damour, Dominique; Clerc, Francois
PATENT ASSIGNEE(S):	Aventis Pharma S.A., Fr.
SOURCE:	PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2006056697	A1	20060601	WO 2005-FR2933		20051125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
FR 2878442	A1	20060602	FR 2004-12644		20041129
EP 1824859	A1	20070829	EP 2005-822880		20051125
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU					
JP 2008521781	T	20080626	JP 2007-542047		20051125
US 20080058402	A1	20080306	US 2007-752612		20070523
PRIORITY APPLN. INFO.:			FR 2004-12644	A	20041129
			WO 2005-FR2933	W	20051125

OTHER SOURCE(S): CASREACT 145:8163; MARPAT 145:8163

GI



I



II

AB Title compds. I [R1 = independently R2, NHCOR2, CH:CH-R2, etc.; R2 = heteroaryl/aryl/heterocyclo/cyclo/alkyl, etc.; R3 = alkyl, alkyl/aryl, alkyl/heteroaryl; with the proviso that when R3 = alkyl, than R1 is not hetero/aryl or CH:CH-R2, where R2 = hetero/aryl; their racemates, enantiomers and diastereomers, and their pharmaceutical addition salts with mineral and organic acids or mineral and organic bases] were prepared as inhibitors of protein kinases, particularly Aurora 2 kinase (data) for treating cancer (no data). E.g., a 7-step synthesis starting from 3,4,5-tribromopyrazole was

given for thienopyrazole II•HCl. II inhibited Aurora 2, CDK2 and Tie2 with IC50 of < 50 nM, < 500 nM and < 500 nM, resp.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:823564 CAPLUS Full-text

DOCUMENT NUMBER: 143:229842

TITLE: Preparation of thieno[2,3-c]pyrazole derivatives as protein kinase inhibitors

INVENTOR(S): Fancelli, Daniele; Bindi, Simona; Varasi, Mario; Vianello, Paola; Vioglio, Sergio; Tesei, Dania

PATENT ASSIGNEE(S): Pharmacia Italia S.p.A., Italy

SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005074922	A1	20050818	WO 2005-EP1021		20050202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2005210114	A1	20050818	AU 2005-210114		20050202
CA 2555262	A1	20050818	CA 2005-2555262		20050202
EP 1711177	A1	20061018	EP 2005-701307		20050202
EP 1711177	B1	20080528			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
CN 1946395	A	20070411	CN 2005-80005922		20050202
BR 2005007375	A	20070710	BR 2005-7375		20050202
JP 2007520513	T	20070726	JP 2006-551790		20050202
AT 396724	T	20080615	AT 2005-701307		20050202
US 20050187209	A1	20050825	US 2005-50360		20050203
IN 2006DN04402	A	20070810	IN 2006-DN4402		20060731
MX 2006PA08787	A	20070119	MX 2006-PA8787		20060802
NO 2006003768	A	20061102	NO 2006-3768		20060823
PRIORITY APPLN. INFO.:			US 2004-541452P	P	20040203
			WO 2005-EP1021	W	20050202

OTHER SOURCE(S): MARPAT 143:229842

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = (un)substituted aryl or heteroaryl; R1 and R2 independently = H, alkyl, CONH2, etc. or together may form cycloalkyl ring

with provisions; R3 = H, halo, OH, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as protein kinase inhibitors. Thus, e.g., II was prepared by amination of 1-(ethoxycarbonyl)-3-[(4- morpholin-4-ylbenzoyl)amino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid hydrochloride (preparation given) with cumylamine and subsequent deprotection. The inhibitory activity of I towards Aurora-2 kinase was evaluated utilizing a scintillation assay and it was revealed that selected compds. of the invention displayed IC50 values below 20 nM. I as protein kinase inhibitor should prove useful in the treatment of cancer. Pharmaceutical compns. comprising I are disclosed.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:120937 CAPLUS Full-text

DOCUMENT NUMBER: 142:219264

TITLE: Preparation of N-sulfonylheterocyclopyrrolylalkylamine compounds as 5-hydroxytryptamine-6 ligands

INVENTOR(S): Cole, Derek Cecil

PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA

SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012311	A1	20050210	WO 2004-US23993	20040723
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004261606	A1	20050210	AU 2004-261606	20040723
CA 2532382	A1	20050210	CA 2004-2532382	20040723
EP 1648904	A1	20060426	EP 2004-757294	20040723
EP 1648904	B1	20070822		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1826346	A	20060830	CN 2004-80021010	20040723
BR 2004013158	A	20061003	BR 2004-13158	20040723
JP 2007500701	T	20070118	JP 2006-521964	20040723
AT 370955	T	20070915	AT 2004-757294	20040723
ES 2290740	T3	20080216	ES 2004-757294	20040723
US 20050038088	A1	20050217	US 2004-909092	20040730
US 7041695	B2	20060509		
IN 2005KN02750	A	20061201	IN 2005-KN2750	20051230
MX 2006PA00957	A	20060330	MX 2006-PA957	20060124
US 20060160878	A1	20060720	US 2006-344765	20060201
US 7220756	B2	20070522		

PRIORITY APPLN. INFO.: US 2003-491622P P 20030731
WO 2004-US23993 W 20040723

US 2004-909092 A3 20040730
OTHER SOURCE(S): CASREACT 142:219264; MARPAT 142:219264
GI


I


II

AB The title compds. I [X = CR7, SOm, O, NR8; Y = CR9, SOm, O, NR8; Z = CR10, SOm, O, NR8 with the proviso that two of X, Y and Z must be CR7, CR9, CR10; R1, R2 = H, OH, alkyl; R3, R4 = H, alkyl, cycloalkyl, etc.; NR3R4 = (un)substituted 5-8 membered ring optionally containing an addnl. heteroatom selected from O, NR11, SOx; R5 = H, halo, alkyl, alkoxy, etc.; R6 = (un)substituted alkyl, cycloalkyl, aryl, etc.; n = 2-5; R7, R9, R10 = H, halo, CN, etc.; R8 = H, alkyl, cycloalkyl, etc.; m, x = 0-2], useful for the therapeutic treatment of a CNS disorder relating to or affected by the 5-HT6 receptor, were prepared E.g., a multi-step synthesis of II, starting from 2-thiophenecarboxylic acid, which showed Ki of 7.5±0.9 nM against 5-HT6 binding, was given. The pharmaceutical composition comprising the compound I is disclosed.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:99176 CAPLUS Full-text
DOCUMENT NUMBER: 142:198080
TITLE: Preparation of substituted thieno[2,3-c]pyrazoles and their use as medicinal products for cancer and neurodegenerative diseases
INVENTOR(S): Bigot, Antony; Clerc, Francois; Doerflinger, Gilles; Mignani, Serge; Minoux, Herve
PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
SOURCE: U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20050026984	A1	20050203	US 2004-900549		20040728
PRIORITY APPLN. INFO.:			FR 2003-9284	A	20030729
			US 2003-500614P	P	20030905

OTHER SOURCE(S): CASREACT 142:198080; MARPAT 142:198080
GI



I

AB The present invention relates in particular to novel chemical compds., particularly novel substituted thieno[2,3-c]pyrazoles I [R1 = XY; X = ; Y = (un)substituted; R2 = XY, ; R = H, alkyl; n = 0 - 2; a = 1, 2; all above are optionally substituted with alkyl, aryl, amino or alkoxy; with the proviso that when R2 = R1, then X ≠ NHCO, NHSO2], to the compns. containing them and to their use as medicinal products for treating cancers and also neurodegenerative diseases. Thus, 3-phenyl-1H-thieno[2,3- c]pyrazole-5-carboxylic acid N-benzyl-N-methylamide [I; R1 = Ph, R2 = CONMeCH2Ph] was prepared from 1-benzyl-5-chloro-3-phenylpyrazole-4- carboxaldehyde via cyclocondensation with HSCH2CO2Et, chlorination with SOCl2 and amidation with PhCH2NHMe. The protein kinase inhibitory activity of I was tested against FAK, KDR, Aurora 2, Src and Tie2 (Ki = 100 - 5000 nM).

L5 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:120860 CAPLUS Full-text
DOCUMENT NUMBER: 140:163864
TITLE: Preparation of condensed heterocyclic pyrazole derivatives as protein kinase inhibitors
INVENTOR(S): Tonani, Roberto; Bindi, Simona; Fancelli, Daniele; Pittala, Valeria; Varasi, Mario
PATENT ASSIGNEE(S): Pharmacia Italia S.P.A, Italy
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013146	A1	20040212	WO 2003-EP7531	20030711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493680	A1	20040212	CA 2003-2493680	20030711
AU 2003250040	A1	20040223	AU 2003-250040	20030711
EP 1530573	A1	20050518	EP 2003-766152	20030711
EP 1530573	B1	20080319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

BR 2003012961	A	20050614	BR 2003-12961		20030711
JP 2005537288	T	20051208	JP 2004-525180		20030711
AT 389658	T	20080415	AT 2003-766152		20030711
MX 2005PA00946	A	20050516	MX 2005-PA946		20050124
US 20060122249	A1	20060608	US 2005-522250		20050919
PRIORITY APPLN. INFO.:			US 2002-398121P	P	20020725
			WO 2003-EP7531	W	20030711

OTHER SOURCE(S): MARPAT 140:163864
GI



I



II

AB The title compds. I [wherein X = O, S, SO, SO2, or NR'; R and R1 = independently H, (un)substituted R', COR', CO2R', CONHR', CONR'R'', SO2R', SO2NHR', or SO2NR'R''; R' and R'' = independently H, (un)substituted alkyl, heterocyclyl, aryl, or aralkyl; R2 = (un)substituted R', CH2OR', or OR'] or pharmaceutically acceptable salts thereof are prepared For example, the compound II was prepared in a five-step synthesis starting from Et 4-cyano-5-(methylthio)thiophene-2-carboxylate. I can be used as protein kinase inhibitors, and are useful for the treatment of cancer (no data).

L5 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:972059 CAPLUS Full-text
DOCUMENT NUMBER: 140:27819
TITLE: Preparation of pyrazole derivatives as JNK inhibitors
INVENTOR(S): Ohi, Norihito; Sato, Nobuaki; Soejima, Motohiro; Doko, Takashi; Terauchi, Taro; Naoe, Yoshimitsu; Motoki, Takafumi
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 561 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101968	A1	20031211	WO 2003-JP6777	20030529

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2482838	A1	20031211	CA 2003-2482838	20030529
AU 2003241925	A1	20031219	AU 2003-241925	20030529
EP 1510516	A1	20050302	EP 2003-733170	20030529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1656079	A	20050817	CN 2003-812475	20030529
US 20050208582	A1	20050922	US 2003-447948	20030530
US 20050261339	A1	20051124	US 2005-509795	20050225
PRIORITY APPLN. INFO.:			JP 2002-158467 A	20020531
			JP 2003-153 A	20030106
			WO 2003-JP6777 W	20030529

OTHER SOURCE(S): MARPAT 140:27819

GI



I

AB The title compds. I [R1 represents (CO)h(NRa)j(CRb:CRc)kAr (wherein Ra, Rb, and Rc each independently represents hydrogen, halogeno, hydroxy, optionally substituted C1-6 alkyl, etc.); Ar = (un)substituted aromatic heterocyclic ring, etc.; h, j, k = 0 or 1; Cy is a 5- or 6-membered aromatic heterocycle; and V represents L-X-Y (wherein L is a single bond, optionally substituted C1-6 alkylene, etc.; X is a single bond, O, CO, etc.; and Y is hydrogen, halogeno, nitro, etc.); n = 0 - 4] are prepared Compds. of this invention in vitro showed IC50 values of 63 nM to 578 nM against JNK-3.

REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:208277 CAPLUS Full-text

DOCUMENT NUMBER: 134:237495

TITLE: Preparation of heteroaromatic amines as protein kinase inhibitors

INVENTOR(S): Hirst, Gavin C.

PATENT ASSIGNEE(S): BASF A.-G., Germany

SOURCE: PCT Int. Appl., 140 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019828	A2	20010322	WO 2000-US25357	20000915
WO 2001019828	A3	20011004		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2385769	A1	20010322	CA 2000-2385769	20000915
AU 2000074914	A	20010417	AU 2000-74914	20000915
BR 2000014075	A	20020716	BR 2000-14075	20000915
TR 200201506	T2	20021021	TR 2002-1506	20000915
EP 1268481	A2	20030102	EP 2000-963510	20000915
EP 1268481	B1	20071212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509427	T	20030311	JP 2001-523405	20000915
NZ 517759	A	20040430	NZ 2000-517759	20000915
HU 2003003363	A2	20040728	HU 2003-3363	20000915
US 7071199	B1	20060704	US 2000-663320	20000915
AT 380814	T	20071215	AT 2000-963510	20000915
ES 2299434	T3	20080601	ES 2000-963510	20000915
IN 2002MN00302	A	20070112	IN 2002-MN302	20020311
ZA 2002002122	A	20030617	ZA 2002-2122	20020314
MX 2002PA02938	A	20041206	MX 2002-PA2938	20020314
NO 2002001329	A	20020521	NO 2002-1329	20020318
BG 106585	A	20030331	BG 2002-106585	20020405
PRIORITY APPLN. INFO.:			US 1999-154618P P	19990917
			WO 2000-US25357 W	20000915

OTHER SOURCE(S): MARPAT 134:237495
GI



I

AB Two title compound, e.g., I, were prepared as protein kinase inhibitors (no data). Thus, NCCH2NHC6H4(OPh)-4 was cyclocondensed with α-formylcyclopentaneacetonitrile (preparation each given) and the product cyclocondensed with HC(:NH)NH2.HOAc to give I.

L5 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1994:298461 CAPLUS Full-text
DOCUMENT NUMBER:	120:298461
ORIGINAL REFERENCE NO.:	120:52597a,52600a
TITLE:	Benzothiophenes amidine and thienothiopheneamidine urokinase inhibitors
INVENTOR(S):	Bridges, Alexander; Schwartz, C. Eric; Littlefield, Bruce A.

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 72 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 568289	A2	19931103	EP 1993-303207	19930423
EP 568289	A3	19940601		
R: CH, DE, FR, GB, IT, LI, NL, SE				
US 5340833	A	19940823	US 1992-877664	19920501
CA 2094332	A1	19931102	CA 1993-2094332	19930419
JP 06049058	A	19940222	JP 1993-102282	19930428
JP 3325076	B2	20020917		

PRIORITY APPLN. INFO.: US 1992-877664 A 19920501
OTHER SOURCE(S): MARPAT 120:298461
GI



AB The title compds. I (R1 = H, NH2, halogen; R2-R5 = H, halogen, HO, NH2, NO2, organic group; R6, R7 = H, C1-6 straight-chain alkyl; such that ≥1 of R2-R5 is a C≥5 organic group) and II (≥1 of X, Y, or Z must be C; ≥1 of X, Y, or Z must be O, N, or S and if ≥1 of X, Y, or Z is O, N, or S than ≥1 of those groups is N), useful in treating cellular invasiveness initiated by urokinase, are prepared Thus, 3-fluoroanisole was formylated into 6-fluoro-2-methoxybenzaldehyde, the intermediate annulated with Me thioglycollate, producing Me 4-methoxybenzo[b]thiophene-2-carboxylate, which was subjected to amidination, producing I (R1 = R3-R7 = H, R2 = OMe) (III). III demonstrated 12% residual urokinase activity at 1 mM in the Urokinase Direct Assay.

L5 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:106287 CAPLUS Full-text
DOCUMENT NUMBER: 116:106287
ORIGINAL REFERENCE NO.: 116:18003a,18006a
TITLE: Preparation of thieno[2,3-c]pyrazole-3,4-diamines
INVENTOR(S): Briel, Detlef; Moschke, Thomas; Wagner, Guenther; Lohmann, Dieter; Hoffmann, Wolfgang; Ploen, Ursula
PATENT ASSIGNEE(S): Karl-Marx-Universitaet Leipzig, Germany
SOURCE: Ger. (East), 6 pp.
CODEN: GEXXA8
DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 294485	A5	19911002	DD 1990-340708	19900516

PRIORITY APPLN. INFO.: DD 1990-340708 19900516
OTHER SOURCE(S): CASREACT 116:106287; MARPAT 116:106287
GI



I



II

AB Title compds. I (R = H, Me; R1 = CO2Me, CO2Et, Bz) were prepared by treating thiophenes II (R2 = alkylsulfonyl) with RNHNH2 with or without isolation of the intermediates II (R2 = NRNH2). Thus, II (R1 = Bz, R2 = MeSO2) was prepared from II (R2 = SH) by methylation and oxidation and was treated with MeNHNH2 in MeOH under reflux followed by HCl-MeOH to give 60% I.HCl (R = Me, R1 = Bz).

=> d his

(FILE 'HOME' ENTERED AT 12:04:32 ON 27 AUG 2008)

FILE 'REGISTRY' ENTERED AT 12:04:41 ON 27 AUG 2008
L1 STRUCTURE UPLOADED

FILE 'CAPLUS' ENTERED AT 12:05:00 ON 27 AUG 2008
S L1

FILE 'REGISTRY' ENTERED AT 12:05:04 ON 27 AUG 2008
L2 315 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 12:05:04 ON 27 AUG 2008
L3 18 S L2 SSS FULL

FILE 'MARPAT' ENTERED AT 12:05:09 ON 27 AUG 2008
L4 14 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 12:05:21 ON 27 AUG 2008
L5 14 S L4

=> file beilstein

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	41.22	346.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.20	-11.20

```
FILE 'BEILSTEIN' ENTERED AT 12:05:56 ON 27 AUG 2008
COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON April 1, 2008

FILE COVERS 1771 TO 2008.
*** FILE CONTAINS 10.322,808  SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
   separate documents and can not be searched together in one query.
   Reaction data for BEILSTEIN compounds may be displayed
   immediately with the display codes PRE (preparations) and REA
   (reactions).  A substance answer set retrieved after the search
   for a chemical name, a compounds with available reaction
   information by combining with PRE/FA, REA/FA or more generally
   with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
   between a BEILSTEIN compound and belonging reactions. For mo
   detailed reaction searches BRNs can be searched as reaction
   partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE  <<<

**********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.                *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE   *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE          *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                        *
* FOR PRICE INFORMATION SEE HELP COST                                *
**********************************************************************

>>> Price change as of January 1st, 2008: Connect Time and Structure
    Search fees re-introduced. See NEWS and HELP COST <<<

=> s L1 SSS full
FULL SEARCH INITIATED 12:06:02 FILE 'BEILSTEIN'
FULL SCREEN SEARCH COMPLETED -       34 TO ITERATE

100.0% PROCESSED       34 ITERATIONS                                7 ANSWERS
SEARCH TIME: 00.00.02

L6             7 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      84.41     430.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -11.20

FILE 'CAPLUS' ENTERED AT 12:06:13 ON 27 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
```

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Aug 2008 VOL 149 ISS 9
FILE LAST UPDATED: 26 Aug 2008 (20080826/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s L6
SEARCH PROFILE NOT SUPPORTED FOR AUTOMATED SEARCH AND CROSSOVER
The search profile contains L-numbers or saved item names that include chemical substance terms, chemical structures, or structure screen sets. If you are in a single file environment using the CA file (CA, HCA, ZCA, CAPLUS, HCAPLUS, ZCAPLUS), enter HELP FIRST at an arrow prompt (=>) for information about the REG1stRY automated search and crossover feature. REG1stRY supports the following search profiles:

Example 1:
```
   => ACT SCRSTR/Q
   L3              STR
   L4              SCR 2127
   L5              QUE  L3 NOT L4

   These searches are supported:
   S  L5/REG
   S  SCRSTR/Q/REG
   S  (L3 NOT L4)/REG

   These searches are not supported:
   S  L5
   S  SCRSTR/Q
```

Example 2:
```
   => ACT SCRSTR2/Q
   L6              STR
   L7              SCR 2127
   L8              QUE  L6
   L9              QUE  L7
   L10             QUE  L8 NOT L9

   This search is supported:
   S  (L6 NOT L7)/REG

   These searches are not supported:
   S  L10
   S  L10/REG
   S  SCRSTR2/Q
   S  SCRSTR2/Q/REG
   S  L8 NOT L9
```

```
   S  (L8 NOT L9)/REG

=> d hib
YOU HAVE REQUESTED DATA FROM FILE 'BEILSTEIN' - CONTINUE? (Y)/N:n


=> d his

     (FILE 'HOME' ENTERED AT 12:04:32 ON 27 AUG 2008)

     FILE 'REGISTRY' ENTERED AT 12:04:41 ON 27 AUG 2008
L1             STRUCTURE UPLOADED

     FILE 'CAPLUS' ENTERED AT 12:05:00 ON 27 AUG 2008
               S L1

     FILE 'REGISTRY' ENTERED AT 12:05:04 ON 27 AUG 2008
L2          315 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 12:05:04 ON 27 AUG 2008
L3           18 S L2 SSS FULL

     FILE 'MARPAT' ENTERED AT 12:05:09 ON 27 AUG 2008
L4           14 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 12:05:21 ON 27 AUG 2008
L5           14 S L4

     FILE 'BEILSTEIN' ENTERED AT 12:05:56 ON 27 AUG 2008
L6            7 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 12:06:13 ON 27 AUG 2008

=> file beilstein
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   0.48     431.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                   0.00     -11.20

FILE 'BEILSTEIN' ENTERED AT 12:06:39 ON 27 AUG 2008
COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON April 1, 2008

FILE COVERS 1771 TO 2008.
*** FILE CONTAINS 10.322,808  SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in
   separate documents and can not be searched together in one query.
   Reaction data for BEILSTEIN compounds may be displayed
   immediately with the display codes PRE (preparations) and REA
   (reactions).  A substance answer set retrieved after the search
   for a chemical name, a compounds with available reaction
   information by combining with PRE/FA, REA/FA or more generally
   with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
   between a BEILSTEIN compound and belonging reactions. For mo
```

```
   detailed reaction searches BRNs can be searched as reaction
   partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE  <<<

*********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.               *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE  *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE         *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                       *
* FOR PRICE INFORMATION SEE HELP COST                               *
*********************************************************************

>>> Price change as of January 1st, 2008: Connect Time and Structure
    Search fees re-introduced. See NEWS and HELP COST <<<

=> s L1 SSS full
FULL SEARCH INITIATED 12:06:43 FILE 'BEILSTEIN'
FULL SCREEN SEARCH COMPLETED -       34 TO ITERATE

100.0% PROCESSED       34 ITERATIONS                                 7 ANSWERS
SEARCH TIME: 00.00.01

L7            7 SEA SSS FUL L1

=> d L7


L7   ANSWER 1 OF 7 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

     Beilstein Records (BRN):        9953417
     Chemical Name (CN):             6-benzyl-5-cyano-3-(p-
                                     nitrobenzamido)pyrrolo<2,3-c>pyrazole
     Autonom Name (AUN):             N-(6-benzyl-5-cyano-1,6-dihydro-
                                     pyrrolo<2,3-c>pyrazol-3-yl)-4-nitro-
                                     benzamide
     Molec. Formula (MF):            C20 H14 N6 O3
     Molecular Weight (MW):          386.37
     Lawson Number (LN):             30356, 14140, 10582
     Compound Type (CTYPE):          heterocyclic
     Constitution ID (CONSID):       8377936
     Tautomer ID (TAUTID):           9317002
     Entry Date (DED):               2005/07/22
     Update Date (DUPD):             2005/07/22
```



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	3
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
ED	Entry Date	1
UPD	Update Date	1
CPD	Crystal Property Description	1
IR	Infrared Spectrum	1
MP	Melting Point	1
MS	Mass Spectrum	1
NMR	Nuclear Magnetic Resonance	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

```
=> d his

     (FILE 'HOME' ENTERED AT 12:04:32 ON 27 AUG 2008)

     FILE 'REGISTRY' ENTERED AT 12:04:41 ON 27 AUG 2008
L1             STRUCTURE UPLOADED

     FILE 'CAPLUS' ENTERED AT 12:05:00 ON 27 AUG 2008
               S L1

     FILE 'REGISTRY' ENTERED AT 12:05:04 ON 27 AUG 2008
```

```
L2          315 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 12:05:04 ON 27 AUG 2008
L3           18 S L2 SSS FULL

     FILE 'MARPAT' ENTERED AT 12:05:09 ON 27 AUG 2008
L4           14 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 12:05:21 ON 27 AUG 2008
L5           14 S L4

     FILE 'BEILSTEIN' ENTERED AT 12:05:56 ON 27 AUG 2008
L6            7 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 12:06:13 ON 27 AUG 2008

     FILE 'BEILSTEIN' ENTERED AT 12:06:39 ON 27 AUG 2008
L7            7 S L1 SSS FULL

=> d L7 1-7


L7   ANSWER 1 OF 7 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

     Beilstein Records (BRN):        9953417
     Chemical Name (CN):             6-benzyl-5-cyano-3-(p-
                                     nitrobenzamido)pyrrolo<2,3-c>pyrazole
     Autonom Name (AUN):             N-(6-benzyl-5-cyano-1,6-dihydro-
                                     pyrrolo<2,3-c>pyrazol-3-yl)-4-nitro-
                                     benzamide
     Molec. Formula (MF):            C20 H14 N6 O3
     Molecular Weight (MW):          386.37
     Lawson Number (LN):             30356, 14140, 10582
     Compound Type (CTYPE):          heterocyclic
     Constitution ID (CONSID):       8377936
     Tautomer ID (TAUTID):           9317002
     Entry Date (DED):               2005/07/22
     Update Date (DUPD):             2005/07/22
```



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	3
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
ED	Entry Date	1
UPD	Update Date	1
CPD	Crystal Property Description	1
IR	Infrared Spectrum	1
MP	Melting Point	1
MS	Mass Spectrum	1
NMR	Nuclear Magnetic Resonance	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

L7 ANSWER 2 OF 7 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	8057083
Chemical Name (CN):	5-phenyl-1H-furo<2,3-c>pyrazol-3-ylamine
Autonom Name (AUN):	5-phenyl-1H-furo<2,3-c>pyrazol-3-ylamine
Molec. Formula (MF):	C11 H9 N3 O
Molecular Weight (MW):	199.21
Lawson Number (LN):	32250
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6868647
Tautomer ID (TAUTID):	7634200
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1999/05/06
Update Date (DUPD):	1999/05/07



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
NMR	Nuclear Magnetic Resonance	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	2
RXREA	Substance is Reaction Reactant	1
RXPRO	Substance is Reaction Product	1

L7 ANSWER 3 OF 7 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7895652
Chemical Name (CN):	4-acetylamino-3-amino-1H-thieno<2,3-c>pyrazole-5-carboxylic acid methyl ester; hydrochloride
Autonom Name (AUN):	4-acetylamino-3-amino-1H-thieno<2,3-c>pyrazole-5-carboxylic acid methyl ester; hydrochloride
Fragm. Molec. Formula (FMF):	C9 H10 N4 O3 S , Cl H
Molecular Formula (MF):	C9 H10 N4 O3 S . Cl H
Molecular Weight (MW):	254.26, 36.46
Fragment BRN (FBRN):	7879351, 1098214
Lawson Number (LN):	32265, 1155, 289
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6718154
Tautomer ID (TAUTID):	7436815
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1998/07/15
Update Date (DUPD):	1998/07/15

CM 1

FBRN 7879351
FMF C9 H10 N4 O3 S



CM 2

FBRN 1098214
FMF Cl H

Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
FMF	Fragment Molecular Formula	2
MF	Molecular Formula	1
FW	Formular Weight	2
FBRN	Fragment BRN	2
LN	Lawson Number	3
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
PHARM	Pharmacological Data	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

L7 ANSWER 4 OF 7 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN): 7721483
Chemical Name (CN): 5-benzenesulfonyl-4-phenyl-1H-thieno<2,3-c>pyrazol-3-ylamine
Autonom Name (AUN): 5-benzenesulfonyl-4-phenyl-1H-thieno<2,3-c>pyrazol-3-ylamine
Molec. Formula (MF): C17 H13 N3 O2 S2
Molecular Weight (MW): 355.43

Lawson Number (LN):	32265, 5222
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6607618
Tautomer ID (TAUTID):	7340598
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1997/11/18
Update Date (DUPD):	1998/03/04



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	2
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
NMR	Nuclear Magnetic Resonance	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	11
RXREA	Substance is Reaction Reactant	9
RXPRO	Substance is Reaction Product	2

L7 ANSWER 5 OF 7 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7450967
Chemical Name (CN):	(3,4-diamino-1H-thieno<2,3-c>pyrazol-5-yl)-phenyl-methanone; hydrochloride
Autonom Name (AUN):	(3,4-diamino-1H-thieno<2,3-c>pyrazol-5-yl)-phenyl-methanone; hydrochloride
Fragm. Molec. Formula (FMF):	C12 H10 N4 O S , Cl H
Molecular Formula (MF):	C12 H10 N4 O S . Cl H
Molecular Weight (MW):	258.30, 36.46
Fragment BRN (FBRN):	7432723, 1098214
Lawson Number (LN):	32264
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6383776
Tautomer ID (TAUTID):	7069215
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1996/08/09
Update Date (DUPD):	1997/04/28

CM 1

FBRN 7432723
FMF C12 H10 N4 O S



CM 2

FBRN 1098214
FMF Cl H

Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
FMF	Fragment Molecular Formula	2
MF	Molecular Formula	1
FW	Formular Weight	2
FBRN	Fragment BRN	2
LN	Lawson Number	1
FS	File Segment	2
CTYPE	Compound Type	1
CONSID	Constitution ID	1

TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
PHARM	Pharmacological Data	2
UVS	UV and Visible Spectrum	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

L7 ANSWER 6 OF 7 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	7449357
Chemical Name (CN):	3,4-diamino-1H-thieno<2,3-c>pyrazole-5-carboxylic acid methyl ester; hydrochloride
Autonom Name (AUN):	3,4-diamino-1H-thieno<2,3-c>pyrazole-5-carboxylic acid methyl ester; hydrochloride
Fragm. Molec. Formula (FMF):	C7 H8 N4 O2 S , Cl H
Molecular Formula (MF):	C7 H8 N4 O2 S . Cl H
Molecular Weight (MW):	212.23, 36.46
Fragment BRN (FBRN):	7429311, 1098214
Lawson Number (LN):	32265, 289
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6379935
Tautomer ID (TAUTID):	7054902
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1996/08/09
Update Date (DUPD):	1997/04/28

CM 1

FBRN 7429311
FMF C7 H8 N4 O2 S



CM 2

FBRN 1098214
FMF Cl H

Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
CN	Chemical Name	1
AUN	Autonomname	1
FMF	Fragment Molecular Formula	2
MF	Molecular Formula	1
FW	Formular Weight	2
FBRN	Fragment BRN	2
LN	Lawson Number	2
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
PHARM	Pharmacological Data	2

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	4
RXREA	Substance is Reaction Reactant	3
RXPRO	Substance is Reaction Product	1

L7 ANSWER 7 OF 7 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN): 4488584
Beilstein Pref. RN (BPR): 105576-69-0
CAS Reg. No. (RN): 105576-69-0
Chemical Name (CN): 3,5-Diamino-4-benzoyl-1,6-dihydropyrrolo<2,3-c>pyrazole
Autonom Name (AUN): (3,5-diamino-1,6-dihydro-pyrrolo<2,3-c>pyrazol-4-yl)-phenyl-methanone
Molec. Formula (MF): C12 H11 N5 O
Molecular Weight (MW): 241.25
Lawson Number (LN): 30357
Compound Type (CTYPE): heterocyclic
Constitution ID (CONSID): 4029357
Tautomer ID (TAUTID): 4302296
Beilstein Citation (BSO): 6-26
Entry Date (DED): 1991/12/02
Update Date (DUPD): 1993/03/20



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	1
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
NMR	Nuclear Magnetic Resonance	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

```
=> d ibib abs hitstr 1-
'IBIB' IS NOT A VALID FORMAT FOR FILE 'BEILSTEIN'
'ABS' IS NOT A VALID FORMAT FOR FILE 'BEILSTEIN'
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'BEILSTEIN'

The following are valid formats:

QRD --------- Query Related Data (IDE plus HIT)
IDE --------- Identification of Substance, plus Structure
ALL --------- All Display fields (Lengthy displaye)
CHE --------- Chemical Data
PHY --------- Physical Data
HIT --------- All fields containing hit terms
Hit terms will be highlighted in all IDE fields in the BEILSTEIN file
A maximum of 20 values are displayed in each single property field.
Use DISPLAY F<prop> for FULL format, e.g. FBP instead of BP.
```

```
For more information about display formats, and how to display
individual selected properties, enter 'HELP FORMAT' at an arrow
prompt, e.g. => HELP FORMAT.
ENTER DISPLAY FORMAT (QRD):end

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 12:07:54 ON 27 AUG 2008
```